Add to ORKGGastric cancer is the second most common cause of cancer related death worldwide. Over 20 % of the advanced gastric cancer are considered to be HER-2 positive. Studies investigating the prognosis of HER-2 positive advanced gastric cancer revealed conflicting results. Trastuzumab, a monoclonal antibody against HER-2, has shown a significant clinical activity in HER-2 positive gastric cancer patients. In this review, I will briefly summarize the clinical studies of anti-HER-2 therapies performed in HER-2 positive gastric carcinoma
Gastric cancer is one of the worldwide leading cancers which is highly prevalent in Eastern Asia. In...
The various treatments for advanced gastric cancer have limitations and induce only marginal surviva...
Purpose: Chemotherapy plus trastuzumab is standard of care for HER2-positive advanced gastric cancer...
Gastric cancer is the second most common cause of cancer related death worldwide. Over 20% of the ad...
Gastric cancer is one of the most common malignancy worldwide with a prognosis less than 1 year in u...
Gastric cancer is a leading cause of cancer-related deaths globally. Human epidermal growth receptor...
Background: Cancer of stomach is the third most common cancer worldwide and often diagnosed at advan...
Surgery is the only curative therapy for gastric cancer. In the metastatic setting the objective of ...
Purpose: At present, a human epidermal growth factor receptor 2 (HER2)-based concept of tumor biolog...
Judith Meza-Junco, Heather-Jane Au, Michael B SawyerDepartment of Oncology, Cross Cancer Institute, ...
The Author(s) 2014. This article is published with open access at Springerlink.com Background In the...
Background: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER...
Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2...
While multimodality treatments, including neoadjuvant and adjuvant chemotherapy or chemoradiation, h...
Gastric cancer remains difficult to cure and has a poor overall prognosis. Chemotherapy and multimod...
Gastric cancer is one of the worldwide leading cancers which is highly prevalent in Eastern Asia. In...
The various treatments for advanced gastric cancer have limitations and induce only marginal surviva...
Purpose: Chemotherapy plus trastuzumab is standard of care for HER2-positive advanced gastric cancer...
Gastric cancer is the second most common cause of cancer related death worldwide. Over 20% of the ad...
Gastric cancer is one of the most common malignancy worldwide with a prognosis less than 1 year in u...
Gastric cancer is a leading cause of cancer-related deaths globally. Human epidermal growth receptor...
Background: Cancer of stomach is the third most common cancer worldwide and often diagnosed at advan...
Surgery is the only curative therapy for gastric cancer. In the metastatic setting the objective of ...
Purpose: At present, a human epidermal growth factor receptor 2 (HER2)-based concept of tumor biolog...
Judith Meza-Junco, Heather-Jane Au, Michael B SawyerDepartment of Oncology, Cross Cancer Institute, ...
The Author(s) 2014. This article is published with open access at Springerlink.com Background In the...
Background: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER...
Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2...
While multimodality treatments, including neoadjuvant and adjuvant chemotherapy or chemoradiation, h...
Gastric cancer remains difficult to cure and has a poor overall prognosis. Chemotherapy and multimod...
Gastric cancer is one of the worldwide leading cancers which is highly prevalent in Eastern Asia. In...
The various treatments for advanced gastric cancer have limitations and induce only marginal surviva...
Purpose: Chemotherapy plus trastuzumab is standard of care for HER2-positive advanced gastric cancer...